MDxHealth SA (MDXH)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $13.75M
Last updated: Nov 17, 2026 at 11:03 AM ET
MDxHealth SA (MDXH) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, MDxHealth SA reported EPS of -$0.16, below the -$0.07 estimate. It beat the EPS estimate in 1 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MDXH's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
MDXH Earnings Call
The latest MDXH earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 23 quarters below that had an estimate, MDXH beat 5 and missed 18. The widest gap in the table came in the quarter ended Sep 30, 2021, when EPS landed 650.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.16 | -$0.07 | -$0.11 - -$0.06 | -128.57% | Miss | N/A | 5 | 5 up, 0 down | Nov 12, 2026 | N/A |
| Jun 30, 2026 | -$0.18 | -$0.12 | N/A | -50.00% | Miss | N/A | 5 | 0 up, 4 down | Aug 13, 2026 | $27.21M |
| Mar 31, 2026 | -$0.17 | -$0.15 | -$0.20 - -$0.11 | -13.33% | Miss | N/A | 5 | 1 up, 2 down | May 13, 2026 | $54.66M |
| Dec 31, 2025 | -$0.17 | -$0.13 | -$0.14 - -$0.12 | -30.77% | Miss | N/A | 5 | 0 up, 3 down | Feb 26, 2026 | $54.66M |
| Sep 30, 2025 | -$0.16 | -$0.11 | -$0.13 - -$0.11 | -45.45% | Miss | N/A | 4 | 0 up, 1 down | Nov 12, 2025 | $27.43M |
| Jun 30, 2025 | -$0.14 | -$0.12 | N/A | -16.67% | Miss | N/A | N/A | 0 up, 0 down | Aug 14, 2025 | $26.61M |
| Mar 31, 2025 | -$0.19 | -$0.13 | N/A | -46.15% | Miss | N/A | N/A | 0 up, 0 down | May 14, 2025 | $24.29M |
| Dec 31, 2024 | -$0.14 | -$0.19 | N/A | +26.32% | Beat | N/A | N/A | 0 up, 0 down | Feb 26, 2025 | $48.06M |
| Sep 30, 2024 | -$0.40 | -$0.25 | -$0.30 - -$0.25 | -60.00% | Miss | N/A | 5 | 0 up, 0 down | Nov 6, 2024 | $23.32M |
| Jun 30, 2024 | -$0.31 | -$0.26 | -$0.29 - -$0.23 | -19.23% | Miss | N/A | 4 | 0 up, 0 down | Aug 21, 2024 | $41.99M |
| Mar 31, 2024 | -$0.31 | -$0.30 | -$0.35 - -$0.27 | -3.33% | Miss | N/A | 4 | 0 up, 0 down | May 1, 2024 | $19.83M |
| Dec 31, 2023 | -$0.39 | -$0.25 | -$0.28 - -$0.02 | -56.00% | Miss | N/A | 3 | 0 up, 0 down | Mar 6, 2024 | $38.75M |
| Sep 30, 2023 | -$0.40 | -$0.19 | -$0.40 - -$0.02 | -110.53% | Miss | N/A | 5 | 2 up, 0 down | Nov 7, 2023 | $19.35M |
| Jun 30, 2023 | -$0.30 | -$0.22 | -$0.39 - -$0.03 | -36.36% | Miss | N/A | 5 | 0 up, 0 down | Aug 23, 2023 | $31.45M |
| Mar 31, 2023 | -$0.50 | -$0.40 | -$0.53 - -$0.04 | -25.00% | Miss | N/A | 4 | 0 up, 0 down | May 15, 2023 | $14.70M |
| Dec 31, 2022 | -$1.10 | -$0.65 | -$0.85 - -$0.53 | -69.23% | Miss | N/A | 3 | 1 up, 0 down | Mar 9, 2023 | $24.05M |
| Sep 30, 2022 | -$0.50 | -$0.53 | -$0.54 - -$0.48 | +5.66% | Beat | N/A | 3 | 1 up, 1 down | Oct 27, 2022 | $11.15M |
| Jun 30, 2022 | -$0.70 | -$0.60 | N/A | -16.67% | Miss | N/A | N/A | N/A | Aug 25, 2022 | $13.01M |
| Mar 31, 2022 | -$0.50 | -$0.53 | -$0.59 - -$0.53 | +5.66% | Beat | N/A | 3 | 0 up, 0 down | Apr 27, 2022 | $6.11M |
| Dec 31, 2021 | -$0.88 | -$0.47 | N/A | -87.23% | Miss | N/A | N/A | 0 up, 0 down | Mar 2, 2022 | $11.51M |
| Sep 30, 2021 | -$4.50 | -$0.60 | N/A | -650.00% | Miss | N/A | N/A | N/A | Nov 5, 2021 | $5.50M |
| Mar 31, 2021 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2021 | $5.06M |
| Dec 31, 2020 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 3, 2021 | $8.58M |
| Sep 30, 2020 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2020 | $4.29M |
| Jun 30, 2020 | -$0.60 | -$1.60 | N/A | +62.50% | Beat | N/A | N/A | N/A | Sep 29, 2020 | $9.88M |
| Mar 31, 2020 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2020 | $4.94M |
| Dec 31, 2019 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2020 | $912000 |
| Sep 30, 2019 | -$0.22 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2019 | $456000 |
| Jun 30, 2019 | -$0.22 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2019 | $10.87M |
| Mar 31, 2019 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2019 | $5.44M |
| Dec 31, 2018 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2019 | $11.20M |
| Sep 30, 2018 | -$0.15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2018 | $5.60M |
| Jun 30, 2018 | -$0.80 | -$1.70 | N/A | +52.94% | Beat | N/A | N/A | N/A | Aug 30, 2018 | $17.20M |
| Mar 31, 2018 | -$0.14 | N/A | N/A | N/A | N/A | -2800.0% | N/A | N/A | Jun 30, 2018 | $8.60M |
| Dec 31, 2017 | -$0.14 | N/A | N/A | N/A | N/A | -2800.0% | N/A | N/A | Mar 31, 2018 | $16.25M |
| Sep 30, 2017 | -$0.13 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2017 | $8.12M |
| Jun 30, 2017 | -$0.13 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2017 | $24.26M |
| Mar 31, 2017 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 30, 2017 | $12.13M |
| Dec 31, 2016 | $0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2017 | $17.02M |
| Sep 30, 2016 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2016 | $8.51M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.66, after -$1.16 the year before. It was -$0.20 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.66 | N/A |
| Dec 31, 2024 | -$1.16 | N/A |
| Dec 31, 2023 | -$1.59 | N/A |
| Dec 31, 2022 | -$2.80 | N/A |
| Dec 31, 2021 | -$5.44 | N/A |
| Dec 31, 2020 | -$0.83 | N/A |
| Dec 31, 2019 | -$0.65 | N/A |
| Dec 31, 2018 | -$1.20 | N/A |
| Dec 31, 2017 | -$0.39 | N/A |
| Dec 31, 2016 | -$0.20 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,400 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,418 | 8 | |
| 2026Q2 | Jun 30, 2026 | 4,285 | 9 | |
| 2026Q1 | Mar 31, 2026 | 3,913 | 7 | |
| 2025Q4 | Dec 31, 2025 | 3,729 | 7 | |
| 2025Q3 | Sep 30, 2025 | 6,101 | 9 | |
| 2025Q1 | Mar 31, 2025 | 6,337 | 10 | |
| 2024Q4 | Dec 31, 2024 | 4,159 | 10 | |
| 2024Q3 | Sep 30, 2024 | 4,533 | 8 |
2026Q3 Earnings Call
Opening remarks
John Fraunces Moderator Before we begin, I would like to remind everyone that the company will make forward-looking statements during today's call. Whether in prepared remarks or during the Q&A session, these forward-looking statements are subject to inherent risks and uncertainties. These risks and uncertainties are detailed in the risk factors section of the company's filings with the Securities and Exchange Commission, specifically in the company's annual report on Form 20-F. I will now turn the call over to Michael McGarrity, Chief Executive Officer.
Michael McGarrity CEO Thanks, John. Thank you all for joining us for our third quarter 2026 earnings conference call. With me today is Ron Kalfus, Interim Chief Financial Officer. Since I joined MDxHealth, we have been consistent in our commitment to transparency, operating discipline, and our core principles of focus, execution, and growth. While our third quarter results fell short of our expectations, that commitment remains unchanged. Simply put, our Q3 results reflected temporary disruption in our commercial execution, driven by accelerated turnover within our sales organization following the discontinuation of Resolve, which was catalyzed by aggressive targeting from outside recruiters. While our disciplined commercial process has served as the foundation of our forecast accuracy and consistent performance over the past four years, that process was clearly disrupted by this recent impact on our sales force. Importantly, we do not believe these factors represent a change in the credibility and reputation we have built with our customer base, the underlying clinical demand for our products, or our long-term market opportunity. However, as I have noted before, you are defined not by what happens to you, but by how you respond. In direct response to this challenge, we have initiated a comprehensive restructuring of our commercial organization designed to reset our focus and process across our sales, marketing, and client services groups. As part of this reorganization, we have eliminated the Chief Commercial Officer role and have effectively split our sales and marketing functions into two distinct operating groups, both of which will report directly to me. Splitting our sales and marketing groups provides clear delineation and direct accountability for product strategy and sales execution, while simultaneously enhancing the overall customer experience. Based on my prior experience operating under this exact model, separating these functions establishes a vital check and balance on what had become a vertical operating structure, giving direct visibility into both territory-level execution and commercial strategy. Over the past several weeks, we have made considerable progress in backfilling and rebuilding our sales team, and we are highly encouraged by the caliber of talent and industry experience we are attracting to MDxHealth. Selection, development, and retention are the foundational pillars of our process through this commercial reset.
Frequently Asked Questions About MDXH
Did MDXH beat earnings estimates last quarter?
No. MDxHealth SA reported EPS of -$0.16 for the quarter ended Sep 30, 2026, below the -$0.07 estimate by 128.57%.
What EPS do analysts expect from MDXH next quarter?
The consensus EPS estimate for MDxHealth SA for the quarter ending Dec 31, 2026 is -$0.09 from 7 analysts, with estimates from -$0.11 to -$0.07.
How often does MDXH beat earnings estimates?
MDxHealth SA beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -38.08%.
MDXH pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts